JW

John Waldheim

Chief Operating Officer

Sorrento Therapeutics

Sorrento Therapeutics Pipeline

DrugIndicationPhase
AbivertinibNon-Small Cell Lung Cancer (NSCLC)Phase 3
Resiniferatoxin (RTX)Severe knee osteoarthritis painPhase 3
OregovomabAdvanced ovarian cancerPhase 3
MSC-1 (anti-LIF mAb)Metastatic solid tumorsPhase 1
SeprehvecRefractory solid tumorsPhase 1
COVID-19 STI-2020 (mAb)COVID-19Phase 2